{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:51:55Z","timestamp":1790779915151,"version":"4.1.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,9,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Fragile X syndrome (FXS) is a genetic condition that causes a range of developmental problems, including intellectual disability, aggressive behavior, anxiety, abnormal sensory processing, and cognitive impairment. Despite intensive preclinical research in Fmr1-targeted transgenic mice, an effective treatment for FXS has yet to be developed. We previously demonstrated that ASP5736, a 5-Hydroxytryptamine (serotonin) receptor 5A receptor antagonist, ameliorated scopolamine-induced working memory deficits in mice, reference memory impairment in aged rats, and methamphetamine-induced positive symptoms and phencyclidine-induced cognitive impairment in animal models of schizophrenia. We hypothesized that ASP5736 may be effective for ameliorating similar behavior deficits in male Fmr1-targeted transgenic rats as a preclinical model of FXS.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We evaluated the effect of acute oral administration of ASP5736 on the abnormal behavior of hyperactivity (0.01, 0.1 mg\/kg), prepulse inhibition (0.01, 0.03, 0.1 mg\/kg), and the novel object recognition task (0.1 mg\/kg) in Frmr1-knockout (KO) rats.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fmr1-KO rats showed body weight gain, hyperactivity, abnormal sensory motor gating, and cognitive impairment. ASP5736 (0.1 mg\/kg) reversed the hyperactivity and ameliorated the sensory motor gating deficits (0.03\u20130.1 mg\/kg). ASP5736 (0.01 mg\/kg) also improved cognitive impairment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>ASP5736 is a potential drug candidate for FXS. Further studies are needed to confirm its clinical efficacy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ijnp\/pyac041","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T22:18:55Z","timestamp":1658873935000},"page":"786-793","source":"Crossref","is-referenced-by-count":8,"title":["5-HT5A Receptor Antagonist ASP5736 Ameliorates Several Abnormal Behaviors in an <i>Fmr1-<\/i>Targeted Transgenic Male Rat Model of Fragile X Syndrome"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1654-1851","authenticated-orcid":false,"given":"Mayako","family":"Yamazaki","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takatomo","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Yarimizu","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyuki","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Drug Discovery Research, Astellas Pharma Inc. , Tsukuba-shi, Ibaraki , Japan"},{"name":"Neuroscience, La Jolla Laboratory, Astellas Research Institute of America LLC , San Diego, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2022092803381485200_CIT0045","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/ng0793-244","article-title":"Human and murine FMR-1: alternative splicing and translational initiation downstream of the CGG repeat","volume":"4","author":"Ashley","year":"1993","journal-title":"Nat Genet"},{"key":"2022092803381485200_CIT0001","doi-asserted-by":"crossref","first-page":"30769","DOI":"10.1038\/srep30769","article-title":"Sensory hypo-excitability in a rat model of fetal development in fragile X syndrome","volume":"6","author":"Berzhanskaya","year":"2016","journal-title":"Sci Rep"},{"key":"2022092803381485200_CIT0002","first-page":"1386","article-title":"Disrupted cortical state regulation in a rat model of fragile X syndrome","volume":"27","author":"Berzhanskaya","year":"2017","journal-title":"Cereb Cortex"},{"key":"2022092803381485200_CIT0044","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0893-133X(99)00096-2","article-title":"The relationship between dorsolateral prefrontal neuronal N-acetylaspartate and evoked release of striatal dopamine in schizophrenia","volume":"22","author":"Bertolino","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"2022092803381485200_CIT0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/j.1469-8986.1978.tb01390.x","article-title":"Prestimulus effects on human startle reflex in normals and schizophrenics","volume":"15","author":"Braff","year":"1978","journal-title":"Psychophysiology"},{"key":"2022092803381485200_CIT0004","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1001\/archpsyc.1992.01820030038005","article-title":"Gating and habituation of the startle reflex in schizophrenic patients","volume":"49","author":"Braff","year":"1992","journal-title":"Arch Gen Psychiatry"},{"key":"2022092803381485200_CIT0006","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1523\/JNEUROSCI.20-10-03864.2000","article-title":"Projections from the rat prefrontal cortex to the ventral tegmental area: target specificity in the synaptic associations with mesoaccumbens and mesocortical neurons","volume":"20","author":"Carr","year":"2000","journal-title":"J Neuroscience"},{"key":"2022092803381485200_CIT0046","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/0006-8993(91)91333-V","article-title":"Side and region dependent changes in dopamine activation with various durations of restraint stress","volume":"550","author":"Carlson","year":"1991","journal-title":"Brain Res"},{"key":"2022092803381485200_CIT0007","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/BF00966870","article-title":"Autoradiographic localization of \u03b3-aminobutyric acid A, receptors within the ventral tegmental area","volume":"17","author":"Churchill","year":"1992","journal-title":"Neurochem Res"},{"key":"2022092803381485200_CIT0008","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/00125817-200109000-00006","article-title":"FMR1- and the fragile X syndrome: human genome epidemiology review","volume":"3","author":"Crawford","year":"2001","journal-title":"Genet Med"},{"key":"2022092803381485200_CIT0009","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3389\/fnmol.2018.00041","article-title":"Of men and mice: modeling the fragile X syndrome","volume":"11","author":"Dahlhaus","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"2022092803381485200_CIT0010","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s11689-017-9186-9","article-title":"Fragile X targeted pharmacotherapy: lessons learned and future directions","volume":"9","author":"Erickson","year":"2017","journal-title":"J Neurodev Disord"},{"key":"2022092803381485200_CIT0042","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/sj.mp.4001432","article-title":"Sensorimotor gating abnormalities in young males with fragile X syndrome and Fmr1-knockout mice","volume":"9","author":"Frankland","year":"2004","journal-title":"Molecular Psychiatry"},{"key":"2022092803381485200_CIT0011","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1152\/jn.90752.2008","article-title":"Imbalance of neocortical excitation and inhibition and altered UP states reflect network hyperexcitability in the mouse model of fragile X syndrome","volume":"100","author":"Gibson","year":"2008","journal-title":"J Neurophysiol"},{"key":"2022092803381485200_CIT0013","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1469-8986.1975.tb01284.x","article-title":"The more or less startling effects of weak prestimuli","volume":"12","author":"Graham","year":"1975","journal-title":"Psychophaygiology"},{"key":"2022092803381485200_CIT0014","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0014-2999(01)00933-5","article-title":"Human 5-HT5 receptors: the 5-HT5A receptor is functional but the 5-HT5B receptor was lost during mammalian evolution","volume":"418","author":"Grailhe","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"2022092803381485200_CIT0015","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/0006-3223(92)90183-Z","article-title":"Startle gating deficits occur across prepulse intensities in schizophrenic patients","volume":"32","author":"Grillon","year":"1992","journal-title":"Biol Psychiatry"},{"key":"2022092803381485200_CIT0016","doi-asserted-by":"crossref","first-page":"17065","DOI":"10.1038\/nrdp.2017.65","article-title":"Fragile X syndrome","volume":"3","author":"Hagerman","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"2022092803381485200_CIT0017","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1037\/a0035988","article-title":"Fmr1- and Nlgn3 knockout rats: novel tools for investigating autism spectrum disorders","volume":"128","author":"Hamilton","year":"2014","journal-title":"Behav Neurosci"},{"key":"2022092803381485200_CIT0041","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ng0193-36","article-title":"Tissue specific expression of FMR-1 provides evidence for a functional role in fragile X syndrome","volume":"3","author":"Hinds","year":"1993","journal-title":"Nat Genet"},{"key":"2022092803381485200_CIT0018","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1037\/0033-295X.87.2.175","article-title":"Reflex modification in the dopamine of startle. I. Some empirical findings and their implications for how the nervous system processes sensory input","volume":"87","author":"Hoffman","year":"1980","journal-title":"Psychol Rev"},{"key":"2022092803381485200_CIT0019","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1121\/1.1910776","article-title":"Acoustic and temporal factors in the evocation of startle","volume":"43","author":"Hoffman","year":"1968","journal-title":"J Acount Soc Am"},{"key":"2022092803381485200_CIT0020","article-title":"Behavioral pharmacological characterization of 5-HT5A receptor antagonists in antipsychologic drug tests","author":"Jongen-Relo","year":"2006"},{"key":"2022092803381485200_CIT0021","doi-asserted-by":"crossref","first-page":"16282","DOI":"10.1523\/JNEUROSCI.3967-14.2015","article-title":"Mouse model of chromosome 15q13.3 microdeletion syndrome demonstrates features related to autism spectrum disorder","volume":"35","author":"Kogan","year":"2015","journal-title":"J Neurosci"},{"key":"2022092803381485200_CIT0022","doi-asserted-by":"crossref","first-page":"18799","DOI":"10.1038\/s41598-020-75893-x","article-title":"Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome","volume":"10","author":"Kozono","year":"2020","journal-title":"Sci Rep"},{"key":"2022092803381485200_CIT0023","doi-asserted-by":"crossref","first-page":"214","DOI":"10.3390\/brainsci8120214","article-title":"Clinical development of targeted fragile X syndrome treatments: an industry perspective","volume":"8","author":"Lee","year":"2018","journal-title":"Brain sciences"},{"key":"2022092803381485200_CIT0024","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/(SICI)1097-4547(19980301)51:5<583::AID-JNR5>3.0.CO;2-B","article-title":"Non-NMDA excitatory amino acid receptors in the ventral tegmental area mediate systemic dizocilpine (MK-801) induced hyperlocomotion and dopamine release in the nucleus accumbens","volume":"51","author":"Math\u00e9","year":"1998","journal-title":"J Neurosci Res"},{"key":"2022092803381485200_CIT0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1006\/geno.1996.0002","article-title":"The chicken FMR1 gene is highly conserved with a CCT 5\u2019-untranslated repeat and encodes an RNA-binding protein","volume":"31","author":"Price","year":"1996","journal-title":"Genomics"},{"key":"2022092803381485200_CIT0026","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1352\/1944-7558-115.6.482","article-title":"Obesity, food selectivity, and physical activity in individuals with fragile X syndrome","volume":"115","author":"Raspa","year":"2010","journal-title":"Am J Intellect Dev Disabil"},{"key":"2022092803381485200_CIT0027","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0014-5793(94)01209-1","article-title":"Cloning and characterisation of the human 5-HT5A serotonin receptor","volume":"355","author":"Rees","year":"1994","journal-title":"FEBS Lett"},{"key":"2022092803381485200_CIT0028","article-title":"Characterization of 5-HT5A antagonists in models of depression and anxiety.","author":"Rueter","year":"2006"},{"key":"2022092803381485200_CIT0029","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/30245","article-title":"Neonatal lesions of the medial temporal lobe disrupt prefrontal cortical regulation of striatal dopamine","volume":"393","author":"Saunders","year":"1998","journal-title":"Nature"},{"key":"2022092803381485200_CIT0030","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1002\/j.1460-2075.1995.tb07237.x","article-title":"FXR1, an autosomal homolog of the fragile X mental retardation gene","volume":"14","author":"Siomi","year":"1995","journal-title":"EMBO J"},{"key":"2022092803381485200_CIT0031","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/oxfordjournals.schbul.a033326","article-title":"Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia","volume":"24","author":"Swerdlow","year":"1998","journal-title":"Schizophr Bull"},{"key":"2022092803381485200_CIT0032","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.pharmthera.2005.12.006","article-title":"5-ht5A receptors as a therapeutic target","volume":"111","author":"Thomas","year":"2006","journal-title":"Pharmacol Ther"},{"key":"2022092803381485200_CIT0033","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/(SICI)1096-8628(19960712)64:1<196::AID-AJMG35>3.0.CO;2-G","article-title":"Prevalence of fragile X syndrome","volume":"64","author":"Turner","year":"1996","journal-title":"Am J Med Genet"},{"key":"2022092803381485200_CIT0034","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00008877-200409000-00018","article-title":"Object recognition impairment in Fmr1 knockout mice is reversed by amphetamine: involvement of dopamine in the medial prefrontal cortex","volume":"15","author":"Ventura","year":"2004","journal-title":"Behav Pharmacol"},{"key":"2022092803381485200_CIT0035","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/0092-8674(91)90397-H","article-title":"Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome","volume":"65","author":"Verkerk","year":"1991","journal-title":"Cell"},{"key":"2022092803381485200_CIT0036","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1128\/MCB.20.22.8536-8547.2000","article-title":"Characterization of dFMR1, a Drosophila melanogaster homolog of the fragile X mental retardation protein","volume":"20","author":"Wan","year":"2000","journal-title":"Mol Cell Biol"},{"key":"2022092803381485200_CIT0037","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.euroneuro.2014.07.009","article-title":"ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia","volume":"24","author":"Yamazaki","year":"2014","journal-title":"Eur Neuropsychopharmacol"},{"key":"2022092803381485200_CIT0038","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jphs.2015.02.006","article-title":"Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats","volume":"127","author":"Yamazaki","year":"2015","journal-title":"J Pharmacol Sci"},{"key":"2022092803381485200_CIT0039","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.euroneuro.2018.03.003","article-title":"Functional mechanism of ASP5736, a selective serotonin 5-HT5A receptor antagonist with potential utility for the treatment of schizophrenia and affective disorders","volume":"28","author":"Yamazaki","year":"2018","journal-title":"Eur Neuropsychopharmacol"},{"key":"2022092803381485200_CIT0040","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/ejn.13406","article-title":"Dopamine receptor activity participates in hippocampal synaptic plasticity associated with novel object recognition","volume":"45","author":"Yang","year":"2017","journal-title":"Eur J Neurosci"}],"container-title":["International Journal of Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ijnp\/advance-article-pdf\/doi\/10.1093\/ijnp\/pyac041\/45288310\/pyac041.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/9\/786\/46107220\/pyac041.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ijnp\/article-pdf\/25\/9\/786\/46107220\/pyac041.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T03:39:07Z","timestamp":1664336347000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ijnp\/article\/25\/9\/786\/6650322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":43,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,7,26]]},"published-print":{"date-parts":[[2022,9,28]]}},"URL":"https:\/\/doi.org\/10.1093\/ijnp\/pyac041","relation":{},"ISSN":["1461-1457","1469-5111"],"issn-type":[{"value":"1461-1457","type":"print"},{"value":"1469-5111","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,9,1]]},"published":{"date-parts":[[2022,7,26]]}}}